Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFILE 1005: Crizotinib in ALK-positive Advanced NSCLC
NCT00932451Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2010
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Objective Response Rate at 6 years and Percentage of Participants With Adverse Events at 6 years. Started Jan 2010; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00932451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932451.